1	Change in Plasma Alpha-Tocopherol Associations with Attenuated Pulmonary Function
2	Decline and with CYP4F2 Missense Variation
3	
4	Jiayi Xu ^{1,2} , Kristin A. Guertin ^{1,3} , Nathan C. Gaddis ⁴ , Anne H. Agler ^{1,5} , Robert S. Parker ¹ ,
5	Jared M. Feldman ¹ , Alan R. Kristal ^{6,7} , Kathryn B. Arnold ⁸ , Phyllis J. Goodman ⁸ , Catherine M.
6	Tangen ⁶ , Dana B. Hancock ⁴ , and Patricia A. Cassano ^{1,9}
7	
8	¹ Division of Nutritional Sciences, Cornell University, Ithaca, NY
9	² Pamela Sklar Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai,
10	New York, NY
11	³ Department of Public Health Sciences, University of Virginia School of Medicine,
12	Charlottesville, VA
13	⁴ GenOmics, Bioinformatics, and Translational Research Center, Biostatistics and Epidemiology
14	Division, RTI International, Research Triangle Park, NC
15	⁵ Abbott, Columbus, OH
16	⁶ Fred Hutchinson Cancer Research Center, Seattle, WA
17	⁷ Department of Epidemiology, University of Washington, Seattle, WA
18	⁸ SWOG Statistical Center, Seattle, WA
19	⁹ Department of Population Health Sciences, Division of Epidemiology, Weill Cornell Medical
20	College, New York, NY
21	
22	Corresponding author:
23	Patricia A. Cassano, PhD
24	Division of Nutritional Sciences, Cornell University
25	209 Savage Hall
26	Cornell University
27	Ithaca, NY 14853
28	pac6@cornell.edu
29	607 255 7551 (ph); 607 255 2691 (fax)

2

30 Abstract

Background: Given its antioxidant activity, vitamin E is hypothesized to attenuate the age-related
decline in pulmonary function.

33 *Objective*: We investigated the association between change in plasma vitamin E (\triangle vitE) and

34 pulmonary function decline and examined genetic and non-genetic factors associated with $\Delta vitE$.

35 *Design*: We studied 1,144 men randomized to vitE in the Selenium and Vitamin E Cancer

36 Prevention Trial. Δ vitE was calculated as the difference between baseline and year 3 vitE

37 concentrations measured with gas chromatography-mass spectrometry. Pulmonary function

38 (forced expiratory volume in the first second [FEV₁]) was measured longitudinally with

39 spirometry. We genotyped 555 participants (vitE-only arm) using the Illumina MEGA^{ex} array.

40 We examined the association of Δ vitE with annual change in FEV₁ using mixed-effects linear

41 regression. We also examined the association of previously reported genetic and non-genetic

42 factors with $\Delta vitE$.

43 *Results*: Greater Δ vitE was associated with attenuated FEV₁ decline, with stronger effects in 44 adherent supplement responders: a 1 SD *higher* Δ vitE (+4 µmol/mmol free-cholesterol-adjusted 45 α -tocopherol) attenuated FEV₁ decline by ~8.9 mL/year (P=0.014). This effect size is ~¹/₄ of the 46 effect of one year of aging, but in the opposite direction. The Δ vitE-FEV₁ association was 47 positive in never and current smokers (9.7 and 11.0 mL/year attenuated FEV₁ decline, 48 respectively), but there was little to no association in former smokers. Greater Δ vitE was 49 associated with *lower* baseline α -tocopherol, *higher* baseline γ -tocopherol, *higher* baseline free 50 cholesterol, European ancestry (vs. African ancestry) (all P<0.0001), and the minor allele of a 51 missense variant in CYP4F2 (rs2108622-T) (2.4 μ mol/L greater Δ vitE; P=0.0032).

- 52 *Conclusions*: Greater response to vitE supplementation was associated with attenuated FEV₁
- 53 decline, and this response was differed by rs2108622 such that individuals with the *C* allele may
- 54 need a higher vitE intake dose to reach the same plasma level, compared to the *T* allele.
- 55
- 56 *Keywords*: vitamin E, pulmonary function tests, *CYP4F2*, human, male, clinical trial, smoking,
- 57 continental population groups, genome-wide association study

4

58 Introduction

59 Vitamin E (vitE) is posited to have beneficial effects on lung health, given its role as a lipid-soluble antioxidant nutrient that scavenges free radicals in cells that can otherwise damage 60 lung and other tissues (1, 2). Among the 8 forms of vitE, alpha-tocopherol (α -TOH) is the most 61 abundant form in the circulation due to preferential post-absorption retention, while gamma-62 63 tocopherol (γ -TOH) is the major form in the U.S. diet (e.g., rich in vegetable oil and nuts). Positive association of vitE with cross-sectional pulmonary function (i.e., measured at a single 64 65 time point) are reported in some (3-15), but not all (6, 11, 16-23) studies. Only two studies 66 investigated associations with longitudinal decline in pulmonary function; a study of dietary 67 intake of vitE with pulmonary function reported little to no association (4), while a study of serum vitE reported an association of lower baseline vitE with steeper decline in pulmonary 68 function in heavy smokers (24). To our knowledge, the Respiratory Ancillary Study (RAS) to the 69 70 Selenium and Vitamin E Cancer Prevention Trial (SELECT) is the only randomized controlled 71 trial (RCT) to investigate the effect of vitE supplementation on pulmonary function decline. The RAS studied 2,920 men and, in an intention-to-treat analysis, reported a non-statistically 72 73 significant (P = 0.19) protective effect of supplementation on decline (-33 mL/year in the vitE 74 arm versus -39 mL/year in the placebo arm), but no evidence for an interaction of vitE 75 supplementation with smoking status (25). 76 RCTs provide high-quality evidence to infer causal effects of nutrition on chronic disease 77 outcomes, but intention-to-treat analyses have often failed to confirm nutrient-disease

78 associations reported in observational studies and/or animal studies (26-28). While the RCT

79 intention-to-treat design preserves randomization and a balance in participant characteristics by

study arm (29), the intention-to-treat analysis may limit inferences for nutrition interventions if

5

the intervention effect varies by individual characteristics including baseline nutriture and
genetic variation. Thus, the efficacy of nutrient supplementation might vary by population
subgroups, which would inform a precision nutrition approach, analogous to the concept of
precision medicine (30).

An *in silico* simulation study reported that genes related to vitE metabolism are highly 85 86 polymorphic (31) making it plausible that genetic differences contribute to inter-individual 87 variation in response to supplementation. Genome-wide association studies (GWAS) have 88 identified several genetic variants associated with cross-sectional plasma vitE concentration (32-89 34), and one study in men who were lifelong heavy smokers reported 2 genome-wide significant 90 variants associated with plasma α -TOH concentration after 3 years of vitE supplementation (35). 91 We investigated the association of change in plasma vitE level (hereafter, $\Delta vitE$), as a biomarker for the response to intervention with a supplement, with age-related decline in 92 93 pulmonary function. We hypothesized that a greater response to vitE supplementation would 94 lead to an attenuated pulmonary function decline in a generally healthy male population and

tested this hypothesis in the RAS using a dose-response analysis. Furthermore, we hypothesized
that genetic and non-genetic factors contribute to inter-individual differences in ΔvitE leading to
sub-populations that benefit differentially from the same level of vitE supplementation.

98

99 *Methods*

100 <u>Study Design and Participants</u>

This study uses data from the RAS to SELECT, which was a phase 3 randomized
controlled double-blinded trial of vitamin E and/or selenium supplementation for prostate cancer
prevention. Details of the RAS and SELECT are published elsewhere (25, 36). Briefly, SELECT

6

104 recruited 35,533 men aged \geq 50 years for African Americans or > 55 years for all other men in 105 the United States, Canada, and Puerto Rico. Eligibility criteria for SELECT included no prostate 106 cancer diagnosis or suspicion of cancer, a serum prostate-specific antigen concentration \leq 4 107 ng/mL, no more than 175 mg/day acetylsalicylic acid or 81 mg/day of acetylsalicylic acid if 108 combined with clopidogrel bisulfate for anticoagulant therapy, a normal blood pressure, and no 109 history of hemorrhagic stroke (36).

110 The RAS included men from 16 SELECT sites and preserved the randomized design. The 111 four study arms were: vitE [400 IU/day of synthetic all rac- α -tocopheryl acetate] + selenium 112 (Se) $[200 \,\mu\text{g/day of L-selenomethionine}]$ (vitE+Se arm); vitE + Se placebo (vitE arm); vitE 113 placebo + Se (Se arm); and vitE placebo + Se placebo (double placebo arm). The safety and 114 efficacy of the supplementation have been considered in the original SELECT Trial (26). The 115 primary endpoint of RAS was annual decline in FEV₁; the secondary endpoint was annual 116 decline in FEF₂₅₋₇₅. These endpoints did not change significantly during the course of study 117 across the intervention arms (25), which led us to the current exploratory analysis using the 118 biomarker change as the exposure, instead of studying the effects of the intervention arms. The 119 Cornell University IRB and the IRB at each of the 16 study sites approved the study. Analyses in 120 this study focused on 1,144 participants of European or African ancestry in the two vitE (vitE or 121 vitE+Se) arms with baseline (pre-intervention) and year 3 (on intervention) plasma vitE blood 122 samples and at least 1 pulmonary function measurement (Figure 1).

123 <u>Pulmonary Function</u>

Pulmonary function, including forced expiratory volume in the first second (FEV₁), was
measured via the EasyOne handheld spirometer, which was previously tested for validity and
reliability (37). The primary endpoint in the RAS was annual rate of change in FEV₁. Pulmonary

7

127 function tests (PFTs) were performed at specified SELECT visits in the RAS participants. Only 128 PFTs meeting ATS standardization criteria (38) were included, and repeated PFTs had to be at 129 least 2 years apart (from the first to the last PFT measure) to be included in our analyses. 130 Vitamin E Plasma vitE was assayed in samples from men in the vitE arms of the study and in a 131 132 random sample of men in the double placebo arm. Blood samples were collected at SELECT 133 baseline (prior to the start of supplements) and at the year 3 annual visit and stored at -80°C for a 134 maximum of 9 years (see **Supplemental Methods**). Plasma α -TOH, γ -TOH and free un-135 esterified cholesterol were assayed via gas chromatography-mass spectrometry (GC-MS) on a 136 Hewlett Packard 6890 gas chromatograph coupled with a Hewlett Packard 6890 mass 137 spectrometer (Palo Alto, CA). Free cholesterol was measured as a proxy for total cholesterol 138 given that the ratio of free to total cholesterol is relatively constant (39). Hereafter, free 139 cholesterol-adjusted TOHs refer to the TOH levels after adjustment of free un-esterified 140 cholesterol (i.e., TOH/cholesterol). Both raw TOH and free-cholesterol-adjusted TOH were used 141 in this study because as a lipid-soluble vitamin, plasma vitE concentration varies by blood lipid levels (40). 142

143 *Genotyping*

Genome-wide genotypes were assayed on a subset of unrelated RAS men in the vitE arm (*n* = 625). The vitE arm was selected for genotyping, rather than the vitE+Se arm, due to potential synergistic effects of Se supplementation. Participant samples of blood buffy coat, collected between 2004 and 2008 at the year 3 annual visit, were stored in a freezer at -80°C in the Human Metabolic Research Unit, Cornell University. In 2011, samples were shipped to the Center for Inherited Disease Research Laboratory, and DNA was extracted from peripheral

8

150 blood leukocytes via the Puregene Blood Kit chemistry on an Autopure LS automated DNA 151 purification instrument (Qiagen, Valencia, CA). In 2016, the Biotechnology Resource Center at 152 Cornell University quantified the DNA concentrations using the Quantifluor dsDNA kit via the 153 Spectra Max M2 plate reader (Molecular Devices, San Jose, CA), and samples were resuspended in the hydration buffer (10mM Tris-Cl, 1mM EDTA, pH 8.0) to normalize 154 155 concentrations, and then sent to the Northwest Genomics Center at University of Washington on 156 dry ice in April 2016 for genotyping. The Illumina Infinium[®] Expanded Multi-Ethnic Genotyping Array (MEGA^{ex}) (Illumina 157 158 Inc., San Diego, CA, USA) was used to genotype more than 2 million genetic markers in 618 159 participants (7 participants were excluded due to very low DNA concentration). After excluding 160 participants with failed call rate (n = 15), genotype data were available for 440 participants of 161 European ancestry [EAs] and 141 participants of African ancestry [AAs]. Quality control (QC) 162 was applied on the genotyped individuals and the single nucleotide polymorphisms (SNPs). At 163 the individual level, the QC filters included: (1) missing call rate > 3%, (2) duplicate sample 164 (identity-by-state > 0.9), (3) first degree relative (identity-by-descent > 0.4), and (4) excessive 165 homozygosity; there were 9 EAs and 1 AA excluded, leaving 431 EAs and 140 AAs. For the 166 genetic analysis of plasma change in TOHs, the final sample size with all covariate information 167 available was 555 ($N_{EA} = 417$, and $N_{AA} = 138$). At the SNP level, the QC filters included: (1) missing rate > 3%, (2) Hardy-Weinberg equilibrium p-value $< 1 \times 10^{-4}$ and (3) duplicate SNPs; 168 169 these QC steps reduced the total genotyped SNP count from 2,036,060 to 1,671,215 for EAs and 170 1,662,290 for AAs. Genotype imputation was then performed based on the Haplotype Reference 171 Consortium panel (version r1.1 2016) (41) using the Michigan Imputation Server. Given the 172 sample size, we focused on variants with minor allele frequency (MAF) > 0.03 in both the

9

ancestry-relevant 1000 Genomes Phase 3 super population (EUR for EAs and AFR for AAs) and
the study population, resulting in a final set of 6,069,665 variants for EAs and 8,944,804 variants
for AAs.

176 <u>Statistical Analysis of Plasma Vitamin E—Pulmonary Function Association</u>

177 A dose-response analysis was used to test the association of change in plasma vitE 178 biomarker levels (α -TOH and γ -TOH) in response to vitE supplementation (" Δ vitE" refers to 179 change in α -TOH, the primary exposure of interest) with annual rate of change in FEV₁ in the two vitE arms. A mixed-effects linear regression model was used to account for the repeated 180 181 PFTs for each participant. The FEV₁ value of each participant at each time point was the 182 dependent variable in the model, with a variable for time as an independent variable that 183 reflected the effect of one year of aging on change in pulmonary function (i.e., annual rate of 184 change in FEV₁). The association of Δ vitE with annual rate of change in FEV₁ was modeled as 185 an interaction term between Δ vitE and the time variable in the linear mixed-effects model (see 186 equation below). The association was adjusted for covariates, including PFT-related factors such 187 as age, height, ancestry, smoking status, cigarettes per day (current smokers only), as well as vitE 188 status-related factors such as treatment arm (vitE arm, vitE+Se arm), baseline α -TOH, γ -TOH, 189 and free cholesterol concentrations.

- 190 $FEV_{1ij} = \beta_0(intercept) + \beta_1(time_{ij}) + \beta_2(\Delta vitE)$
- 191 + $\beta_3(\Delta \text{ vitE} \times \text{time}_{ij}) + \mu_i(\text{random effect of subject/individual})$
- 192 + ε_{ii} (random error) + (other covariates)
- 193 where $i = i^{\text{th}}$ individual, $j = j^{\text{th}}$ PFT measure

194 Sensitivity analyses explored subgroups where we hypothesized a stronger Δ vitE-FEV₁ 195 association. The first sensitivity analysis limited participants to those who were adherent to the

10

196 intervention, defined as using $\geq 80\%$ of the vitE supplement pills. Next, the analysis was further 197 limited to adherent men who were responders to the vitE supplementation. Given that there was a 198 decrease in plasma vitE concentration over 3 years, on average, in a subset of randomly selected 199 participants in the placebo arm (n = 91; mean Δ vitE -3.8 μ mol/L), responders to the vitE 200 supplementation in the two intervention arms were defined as participants with a plasma $\Delta vitE$ 201 value greater than the mean Δ vitE in the placebo arm. We chose the mean Δ vitE in the placebo 202 arm as the reference point, instead of 0 (i.e., no change), because the change in plasma vitE over 203 3 years without a supplement is best estimated by the Δ vitE value in the placebo group (Figure 204 2). Results were robust to this choice. 205 The significance threshold for all analyses was set at two-sided $P \leq 0.05$. Non-linearity

was examined by including a square term for $\Delta vitE$. The influence of one outlier for $\Delta vitE$ was examined by comparing the results with and without the outlier. Possible effect modification of the $\Delta vitE$ -FEV₁ association by smoking status, by treatment arm, and by ancestry was examined in separate models via a 3-way interaction term (each putative effect modifier × $\Delta vitE$ × time).

210 <u>Statistical Analysis of Non-Genetic Factors on $\Delta vitE$ </u>

211 We completed a systematic search of the literature for reports of non-genetic factors 212 associated with plasma vitE concentration. For each factor identified, a further literature review 213 sought to identify the biological plausibility of the putative association (Supplemental 214 **methods**), leading to a final set of factors that were tested individually and then simultaneously 215 in joint models. The variables tested were ancestry, intervention arm, and smoking status 216 measured over the course of the study, and baseline values for age, BMI, α -TOH concentration, 217 γ -TOH concentration, free cholesterol concentration, plasma Se concentration, and dietary 218 intakes of vitamin C, fiber, alcohol. The dietary information was collected by a 120-item food

11

219	frequency questionnaire (FFQ) administered at study baseline (42) to assess average food intake
220	during the preceding 12 months, developed by the Nutrition Assessment Shared Resource
221	(NASR) of Fred Hutchinson Cancer Research Center (Seattle, WA). Nutrient calculations were
222	performed using the Nutrient Data System for Research (NDSR) software (version 2010),
223	developed by the Nutrition Coordinating Center, University of Minnesota (Minneapolis, MN).
224	For smoking status over the course of the study, we categorized the participants into never,
225	former (stopped smoking prior to enrollment), intermittent (on and off smoking during the
226	study), and persistent smokers to account for changes over the course of the study. We grouped
227	intermittent and persistent smokers (i.e., current smokers during the study) to increase the power
228	to detect associations. Linear regression models in SAS (version 9.4, SAS Institute, Cary, NC)
229	tested the association of non-genetic factors with both raw $\Delta vitE$ and free-cholesterol-adjusted
230	Δ vitE. The total R ² denoted the percent of variability in Δ vitE explained by the full model, and
231	the individual R ² denoted the estimated variability explained by each individual factor (e.g.,
232	ancestry, baseline TOH concentration), which was calculated as the difference between total R^2
233	with and without the factor in the model.

234 <u>Statistical Analysis of Genetic Variants on ΔvitE</u>

We conducted agnostic (i.e., GWAS) analyses in order to identify SNPs associated with Δ vitE. We tested SNPs for associations under an additive model using imputed genotype dosage values (a fractional value between 0 and 2 indicating the expected number of minor allele copies) to account for any imputation uncertainty (43). GWAS analyses stratified by ancestry (N_{EA} = 417, N_{AA} = 138) were performed in rvtests (44) and then meta-analyzed using METAL (45) for each of four vitE phenotypes (raw Δ vitE, free-cholesterol-adjusted Δ vitE, raw $\Delta\gamma$ -TOH, and freecholesterol-adjusted $\Delta\gamma$ -TOH) in models adjusted for age, baseline TOH concentration, and

principal components to account for population substructure. We used the GWAS results to

242

243	conduct in-silico look-up associations for two SNPs that were discovered in a previous GWAS of
244	post-vitE-supplementation plasma α -TOH in heavy smokers ($P < 5 \times 10^{-7}$, accounting for 549,989
245	tested SNPs in the previous study) (35); we applied a Bonferroni-corrected p-value threshold of
246	0.025 (α =0.05/2 SNPs). Any SNPs that we replicated were further examined in models that
247	included additional adjustment for the set of previously reported non-genetic covariates
248	(Supplemental Methods) using SAS (version 9.4), which were not included in our parsimonious
249	GWAS model that was designed to optimize statistical power.
250	
251	Results
252	Participant Characteristics
253	1,144 participants were included in the model of annual rate of change in FEV ₁ ,: $N_{EA} =$
254	874 (76.4%) and $N_{AA} = 270$ (23.6%). The mean age of included participants was 63 years, and
255	most participants had a history of smoking (49% former smokers, 19% current smokers) (Table
256	1) and were overweight (48%) or obese (34%).
257	On average, participants in the vitE arms showed an <i>increase</i> in plasma α -TOH after 3
258	years of vitE supplementation; the mean (SD) increase in plasma α -TOH was 8.2 (12.5) μ mol/L
259	in the vitE arm and 7.4 (14.5) μ mol/L in the vitE+Se arm (Supplemental Table 1). In contrast,
260	plasma α -TOH among participants in the double placebo arm (no vitE supplementation)
261	decreased on average [mean Δ : -3.8 µmol/L α -TOH (SD = 8.5), $P = 4.9 \times 10^{-5}$, Figure 2].
262	Participants in the double placebo arm who reported use of pre-study vitE supplementation (>50
263	IU/d α -TOH or with other multivitamins) (17%) had a greater decrease in their plasma vitE level
264	over 3 years (mean $\Delta vitE = -19$ umol/L vs2.4 umol/L for participants not reporting pre-study

265	vitE supplementation). For participants in the vitE arms, the increase in plasma vitE level was
266	lower in participants who took pre-study vitE supplements (21%) (mean Δ vitE = +2.7 umol/L vs.
267	+9.2 umol/L for those who did not take pre-study vitE supplementation).
268	Consistent with the change in plasma α -TOH, there was a notable change in plasma γ -
269	TOH in participants in the vitE arms; plasma γ -TOH decreased by an average of 1.7 μ mol/L in
270	both vitE arms (SD = 2.4 and 2.6, respectively, in vitE arm and vitE+Se), but there was little to
271	no change in the double placebo arm [mean Δ : +0.5 µmol/L (SD = 2.9), $P = 0.10$]
272	(Supplemental Table 1). Six percent of participants were at risk of vitE deficiency at baseline
273	using the clinical threshold of 12 μ mol/L (46), and this dropped to 2% in the vitE arms after 3
274	years of supplementation. The two vitE intervention arms were similar in baseline characteristics
275	and change in plasma tocopherol concentrations (Table 1 and Supplemental Table 1).
276	Although there was a statistically significant difference in BMI ($P = 0.0019$), the difference was
277	not considered biologically meaningful with mean BMI of 29.3 in the vitE arm and 28.4 in the
278	vitE+Se arm. While there was little to no correlation between baseline concentrations of α -TOH
279	and γ -TOH in participants in the two vitE arms (Pearson $r = 0.018$, P=0.53), there was an inverse
280	correlation between Δ vitE and $\Delta\gamma$ -TOH (Pearson $r = -0.22$, P<0.0001).
281	The mean increase in Δ vitE after 3-years of supplementation was significantly higher in
282	EAs compared with AAs in the vitE arm ($P_{EA vs AA} = 0.010$, 9.0 µmol/L versus 5.9 µmol/L,
283	respectively), with similar direction, but lower magnitude differences in the vitE+Se arm ($P_{EA vs}$
284	$_{AA} = 0.60, 7.5 \ \mu mol/L \ versus 6.9 \ \mu mol/L)$. The greater increase in plasma vitE levels in EAs was
285	not related to differences by ancestry group in pre-study vitE supplement use (i.e., a greater
286	increase due to less pre-study vitE use). Indeed, the proportion of EAs reporting pre-study vitE
287	supplement use was greater (23%) compared to AAs (13%).

14

288

289 Plasma AvitE and Longitudinal Pulmonary Function Decline

290	Plasma Δ vitE was associated with longitudinal FEV ₁ decline in adherent participants who
291	responded to the vitE supplement ($\Delta vitE \ge -3.8 \mu mol/L$) (Table 2), and there was little to no
292	association of $\Delta\gamma$ -TOH (Supplemental Table 2). In the full sample, an increase of 1 μ mol/mmol
293	in free-cholesterol-adjusted Δ vitE was associated with a 0.96 mL/year (SD=0.60) attenuation in
294	annual FEV ₁ decline ($P = 0.11$). The effect size increased in sensitivity analyses as follows: men
295	adherent to the intervention [increase of 1 μ mol/mmol in free-cholesterol-adjusted Δ vitE
296	associated with a +1.36 mL/year (SE = 0.78) attenuation in annual FEV ₁ decline, $P = 0.082$];
297	adherent participants who responded to the vitE supplementation [+2.22 mL/year (SD = 0.90), P
298	= 0.014]. Overall, there was evidence that an increase in free-cholesterol-adjusted $\Delta vitE$ was
299	associated with attenuation in FEV ₁ decline, with no evidence of non-linearity ($P = 0.69$). In
300	adherent participants who responded to the intervention, a 1 SD greater $\Delta vitE$ (~4 μ mol/mmol
301	free cholesterol) was associated with an attenuation of ~9 mL/year in FEV ₁ decline. Consistent
302	trends were observed for Δ vitE without adjusting free cholesterol (Table 2).
303	Smoking status modified the association of plasma Δ vitE with FEV ₁ decline (P _{smoking}
304	$_{interaction} < 0.05$, Table 2). An increase in free-cholesterol-adjusted $\Delta vitE$ was significantly
305	associated with attenuation in FEV ₁ decline in never smokers ($P = 0.017$) with a similar but not
306	statistically significant trend in current smokers ($P = 0.079$), and, contrary to expectation, little to
307	no association in former smokers ($P = 0.45$, Table 2). To put the effect magnitude in context, 1
308	SD higher free-cholesterol-adjusted $\Delta vitE$ (~4 $\mu mol/mmol$ free cholesterol) was associated with
309	9.7 mL/yr and 11.0 mL/yr attenuation in FEV1 decline in never and current smokers,

310 respectively. The same trend was observed for raw $\Delta vitE$ (**Table 2**), and in sensitivity analysis

15

311	limited to	adherent mer	(Suppleme	ental Table 3).	. Neither ancestry	y (AA	A, EA) nor treatment arm
-----	------------	--------------	-----------	-----------------	--------------------	-------	-------	---------------------

- 312 (vitE, vitE+Se) modified the association of Δ vitE with FEV₁ decline (P_{interaction} = 0.85 and 0.43)
- 313 for ancestry and treatment arm, respectively).
- 314 Non-Genetic Factors and Plasma AvitE

Plasma Δ vitE values ranged from -55 μ mol/L to +109 μ mol/L in the two vitE arms

- **316** [Figure 2, mean (SD) of 7.8 (13.5), with no difference between arms, P = 0.68]. *Higher* α -TOH
- at the study baseline was associated with a *lower* increase in Δ vitE (P < 0.0001), while *higher*
- 318 free cholesterol and *higher* γ -TOH at baseline were associated with a *greater* increase in Δ vitE
- 319 (P < 0.0001) (**Table 3**). Ancestry was associated with ΔvitE (P < 0.0001), with a smaller
- 320 increase in Δ vitE in African American men and generally this pattern persisted regardless of
- 321 smoking status (Supplemental Table 4). There was little to no association between age, BMI,
- 322 smoking status, and other nutrition factors, including baseline plasma Se concentration, dietary
- intake of vitamin C, fiber, and alcohol in relation to ΔvitE (P > 0.05). Overall, we saw consistent
- findings between raw and free-cholesterol-adjusted $\Delta \alpha$ -TOH (**Table 3**). The fully adjusted model
- explained 18.7% of the variability (\mathbb{R}^2) in Δ vitE in the two vitamin E arms (n = 1, 144), and
- baseline concentrations of α -TOH, γ -TOH, free cholesterol and ancestry explained 10.9%, 1.7%,
- 327 1.2%, and 1.6% of the variability, respectively.
- 328 *Genetic Factors and Plasma AvitE*

GWAS analyses revealed no genome-wide significant loci ($P < 5 \times 10^{-8}$) for change in

- 330 TOH concentration (either α or γ -TOH) in the vitE arm (results not shown). We used the GWAS
- results to study 2 SNPs (rs964184 and rs2108622) that were previously reported in a GWAS of
- 332 circulating α-TOH measured after 3-years of vitE supplementation in male current smokers, but
- were not tested for replication (35). We replicated one SNP: rs2108622 was associated with

334	Δ vitE after 3 years of vitE supplementation in the healthy male participants in the RAS, with <i>P</i> -
335	value passing the Bonferroni-corrected threshold for replication ($P < 0.025$). Rs2108622, a
336	missense SNP in the cytochrome P450 family 4 subfamily F member 2 (CYP4F2) gene on
337	chromosome 19, was directly genotyped on the MEGAex array, so its dosages were 0 (major
338	allele homozygote), 1 (heterozygote), and 2 (minor allele homozygote). When the genotype was
339	modeled as a categorical variable, heterozygotes for the rs2108622 minor allele (CT genotype)
340	had a +1.75 μ mol/L Δ vitE, compared to homozygotes for the major allele (<i>CC</i> genotype),
341	whereas homozygotes for the minor allele (TT genotype) had a +5.66 μ mol/L Δ vitE, compared to
342	CC genotype.
343	The mean Δ vitE for participants with 0, 1, 2 minor alleles of rs2108622 was 7.6 μ mol/L,
344	9.5 μ mol/L, 12.7 μ mol/L in EAs, and ancestry-specific analyses revealed a consistent direction
345	of association for rs2108622 (P = 0.61 for interaction with ancestry; mean Δ vitE for 0, 1, 2 minor
346	alleles was 5.8 μ mol/L, 6.0 μ mol/L, 12.9 μ mol/L in AAs). Thus, findings with the two ancestries
347	combined are presented herein. In the fully adjusted model where the number of SNP alleles was
348	modelled as a continuous variable, each additional copy of the rs2108622-T minor allele
349	(frequency = 31% in EAs and 13% in AAs) was associated with 2.36 μ mol/L greater increase in
350	Δ vitE (P = 0.0032, Table 4), compared to the <i>C</i> major allele. This effect magnitude is ~20% of 1
351	SD of $\Delta vitE$ in the vitE arm (SD = 12.5 μ mol/L). In addition, this SNP explained about a third of
352	the variability (R^2) in $\Delta vitE$ that was initially explained by ancestry (without rs2108622 in the
353	model, ancestry explained ~2.5% of Δ vitE variability; with rs2108622 in the model, ancestry
354	explained ~1.7% of Δ vitE variability). A consistent direction of association was observed in
355	models of free-cholesterol-adjusted $\Delta \alpha$ -TOH, but findings were not statistically significant (P =
356	0.33). There was no evidence for rs2108622 \times smoking interaction (P = 0.65). The fully adjusted

17

357	model explained 18.3% of the variability in plasma $\Delta \alpha$ -TOH in the vitE arm ($n = 555$): baseline
358	concentrations of α -TOH, γ -TOH, free cholesterol, ancestry, and rs2108622-T explained 9.2%,
359	1.7%, 1.3%, 1.7%, and 1.3% of the variability, respectively.

360

361 Discussion

We hypothesized that the effect of vitE supplementation on pulmonary function decline 362 363 would vary across participants in an RCT because of inter-individual variability in the response 364 to vitE supplementation. To address this question, we estimated the longitudinal association of 365 change in vitE status with change in pulmonary function using a dose-response analysis that 366 leveraged a biomarker (change in plasma-measured vitE level) to quantify the treatment 367 exposure. We hypothesized that the associations would be stronger using this more direct 368 measure of treatment exposure compared to the intention-to-treat analysis based on the treatment 369 assignment. Our findings supported the hypothesis, showing that an increase in Δ vitE was 370 associated with an attenuated decline in FEV₁ in this RCT of generally healthy males \geq 50 years 371 of age, particularly in sensitivity analyses focused on adherent vitE supplement responders, such 372 that a 1 SD greater increase in plasma free-cholesterol-adjusted $\Delta vitE$ had an effect on FEV₁ 373 decline that was about one-quarter of the effect of a year of aging, but in the opposite direction. 374 Smoking modified the association such that the beneficial effect of vitE supplementation was 375 statistically significant in never smokers, with less significant effects in current smokers, and 376 little to no effect in former smokers.

To the best of our knowledge, the only prior longitudinal study, which investigated the
association of serum α-TOH at study baseline with 8-year decline in pulmonary function,
reported that heavy smokers with low baseline serum α-TOH concentration predicted the

380	steepest FEV_1 decline (24). The previous intention-to-treat analysis in the RAS (25) estimated
381	the treatment effect by study arm and reported a beneficial, but not statistically significant ($P =$
382	0.19), effect of vitE supplementation on longitudinal pulmonary function; the mean rate of
383	decline in FEV ₁ in the vitE arm was -33 mL/year compared to -39 mL/year in the placebo arm.
384	The early termination of SELECT led to a loss of power in the RAS to detect the intervention
385	effects. The dose-response findings reported herein using the $\Delta vitE$ biomarker support a
386	beneficial effect of vitE supplementation on preservation of pulmonary function. These findings
387	warrant further study to consolidate the causal inference and indicate that exploring inter-
388	individual response to nutrition interventions is informative.
389	Prior studies reported that current smokers experienced a faster disappearance of α -TOH
390	in the circulation and used more α -TOH to combat oxidative stress compared to nonsmokers (47,
391	48). However, even though we found a significantly lower vitE concentration at baseline in
392	current smokers compared to never and former smokers (19.6 μ mol/L, 22.4 μ mol/L, and 22.5
393	μ mol/L, respectively, <i>P</i> < 0.0005), there was no difference in Δ vitE by smoking status after 3-
394	year vitE supplementation (7.8 μ mol/L, 8.0 μ mol/L, and 7.7 μ mol/L, respectively, $P > 0.75$). Our
395	test of effect modification by smoking status led to the unexpected finding that an increase in
396	vitE attenuated pulmonary function decline in never smokers and current smokers, but not in
397	former smokers. Future studies are needed to replicate the smoking-modified effect observed in
398	this study and, if confirmed, to investigate tissue-specific α -TOH concentrations after vitE
399	supplementation across all smoking groups so as to better understand the mechanism.
400	We further hypothesized that genetic variation may contribute to the inter-individual
401	variability in Δ vitE. We found that the minor allele (<i>T</i>) of rs2108622 on <i>CYP4F2</i> was associated
402	with greater ΔvitE (<i>P</i> = 0.0032), and this finding partly explained the association of ancestry

403	with $\Delta vitE$. In the fully adjusted model, rs2108622 explained variability in $\Delta \alpha$ -TOH equivalent
404	to that explained by plasma free cholesterol, which is a key predictor of plasma α -TOH
405	concentration. This CYP4F2 SNP (rs2108622) passed genome-wide significance in a previous
406	GWAS of Δ vitE conducted in a male heavy smoker population, but the finding was not
407	replicated prior to the study reported herein. Given our population of healthy males, the
408	replication provides important evidence in support of the generalizability of this finding.
409	The enzyme encoded by the $CYP4F2$ gene has been shown to be the only one among the
410	cytochrome P450 enzymes that has ω -hydroxylase activity for vitE catabolism (e.g., α - and γ -
411	TOH) in the liver (49, 50). The rs2108622-T allele results in a methionine, instead of a valine, at
412	position 433 of the CYP4F2 enzyme, and a prior study showed that the CYP4F2 enzyme goes
413	through faster degradation by the proteasome (51) when methionine is present. If true, persons
414	with the <i>T</i> allele would have more α -TOH in the liver available for α -TTP transport into the
415	circulation, leading to higher plasma α -TOH. Consistent with this proposed mechanism, we
416	observed that the EA population, with a higher frequency of rs2108622-T minor allele (31%
417	versus 13% in AA, similar to those in the 1000 Genomes Project European [29%] and African
418	[8%] populations), had a greater $\Delta \alpha$ -TOH after supplementation. A candidate gene study of 2
419	SNPs on the CYP4F2 gene also reported an association of rs2108622-T with a greater increase in
420	plasma vitE in patients with nonalcoholic fatty liver disease (52).
421	Several limitations deserve mention. First, at the time of this study, genotype data were
422	available only for participants in the vitE arm ($n = 555$), which limited power to detect
423	significant associations at the genome-wide threshold ($P < 5 \times 10^{-8}$). Nevertheless, we replicated
424	one missense SNP (rs2108622) reported in a previous GWAS, surpassing the Bonferroni-
425	corrected p-value threshold for testing two candidate SNPs ($P < 0.025$) (35). Secondly, while our

426	study did not measure all non-genetic factors identified in the prior literature related to plasma
427	vitE, such as waist circumference (WC) and waist-to-hip ratio (WHR) (53), the factors we
428	investigated were representative of the unmeasured ones (e.g., $r > 0.60$ for the correlations of
429	BMI with WC and WHR (54, 55)). Third, the randomized treatment group variable was retained
430	in models because plasma Δ vitE was used to quantify the biological dose of the treatment
431	exposure in the vitE intervention arms rather than the initial intent-to-treat assignment. We found
432	that the association of $\Delta vitE$ with pulmonary function was largely unchanged with and without
433	adjusting for potential confounding factors (e.g., age, smoking status, baseline nutriture),
434	although we cannot fully rule out residual confounding. Finally, because the RAS participants
435	were overall healthy males over 50 years old, the generalizability of the study may be limited,
436	and whether the same findings would apply to females, to COPD patients, or to other ancestries
437	beyond EAs and AAs needs further investigation.
438	In addition, there are several important considerations. First, regarding the timing of the
439	study intervention and the measurement of PFTs, since the RAS was a post-randomization
440	ancillary study to SELECT, no PFT data were available for the pre-intervention time period.
441	Study supplementation was discontinued in October 2008 due to no benefit of the intervention on
442	prostate cancer (36). Although PFTs were measured beyond the end of supplementation, only
443	PFTs measured prior to March 1, 2009 were included in order to provide a conservative estimate
444	of the effect of vitE intervention (4 months beyond the termination of supplements). Moreover,
445	due to the discontinuation of SELECT, 65% of RAS participants completed \geq 2 PFTs, leading to
446	a loss of power in the intention-to-treat analysis by not having longitudinal PFT measures
447	available on the full cohort (25). Given that the termination of study supplementation was an
448	independent event unrelated to the timing of annual study visits for the participants, we assumed

449	that the RAS men with \geq 2 PFTs comprised a random sample of the entire RAS population. In
450	support of this assumption, the distribution of baseline characteristics including age, height, body
451	mass index (BMI), ancestry, and smoking status were similar comparing men with and without
452	\geq 2 PFTs (data not shown). Finally, the findings were consistent in analyses of Δ vitE or
453	cholesterol-adjusted Δ vitE although not all findings were statistically significant.
454	This study examines both non-genetic and genetic factors related to $\Delta vitE$ after vitE
455	supplementation in a generally healthy population, with valid and reproducible measurements of
456	longitudinal plasma vitE status (baseline and year 3, Supplemental methods) and pulmonary
457	function (1–5 times per individual). Previous studies investigating the determinants of plasma α -
458	TOH were mostly cross-sectional (53, 56-65) or based on interventions with small numbers of
459	participants (n < 50) (66, 67). The present study is unique in considering Δ vitE in a relatively
460	large sample size ($n = 1,144$), which is important given inter-individual variability in Δ vitE.
461	To summarize, a greater change in plasma Δ vitE with vitE supplementation was
462	associated with an attenuation in FEV1 decline, which may indicate a feasible intervention to
463	mitigate pulmonary function decline. In addition, we replicated one missense variant, rs2108622
464	in the <i>CYP4F2</i> gene, from a previous GWAS of Δ vitE in heavy smokers, which could partially
465	explain variability in Δ vitE after supplementation, as observed in our population of healthy males
466	over 50 years old. This genetic finding contributes to the evidence base for precision nutrition by
467	supporting that genetic subgroups respond differentially to dietary supplementation. Thus,
468	participants with the rs2108622-T minor allele may need less vitE supplement, compared with
469	individuals without this allele, to achieve the same amount of increase in plasma Δ vitE.

22

Acknowledgments

We thank Alison Munson, John Le Barre, and Rachel Grant who were undergraduate research assistants contributing to the analytic work on the association of plasma vitE with pulmonary function and the vitE assay work. We also thank Professor Andrew Clark in the Department of Biological Statistics and Computational Biology at Cornell University for providing advice on the analysis and interpretation of the genetic findings. We would also like to thank Vicky A. Simon in the Human Nutritional Chemistry Service Laboratory at Cornell University for her assistance with the inventory and transferring of the DNA samples. We thank Jing Wu and the Biotechnology Resource Center (BRC) Genomics Facility at Cornell's Institute of Biotechnology for the quantification and re-adjustment of the DNA sample concentrations. We also want to thank the BRC Bioinformatics Facility for the storage and computational support of the genomic data. In addition, we want to thank Bonnie K. Patchen, PhD candidate in our research group, for providing insight into the interpretation of results. Last but not least, the authors also thank the SELECT/RAS staff, other investigators and the participants of the RAS study for their valuable contributions.

Conflict of Interest

The authors have no conflict of interest.

Authorship's contribution

JX, KAG, and PAC conceived and designed the study; NCG imputed the genome-wide data; JX, KAG, and NCG analyzed the data. JX, KAG, JMF, ARK, KBA, PJG, CMT, DBH, and PAC interpreted the results; AHA and RSP conducted the vitE assays; PAC, ARK, and CMT

23

designed RAS; PAC, KAG, AHA, and PJG collected data; JX, KAG, DBH, and PAC drafted the manuscript and had primary responsibility for final content; and all authors contributed to critical revision in preparation for publication.

Data sharing

Data described in the manuscript, code book, and analytic code will be made available upon request.

Funding

This research was supported by the National Heart, Lung, and Blood Institute (NHLBI) grants R01 HL071022 and R21 HL125574, and the National Cancer Institute/Division of Cancer Prevention grants U10 CA37429 and 5UM1CA182883. Genotyping services were provided through the RS&G Service by the Northwest Genomics Center at the University of Washington, Department of Genome Sciences, under U.S. Federal Government contract number HHSN268201100037C from the NHLBI. This research was also supported, in part, by the Cornell University Center for Vertebrate Genomics Scholarship Award (to J Xu), and the American Society for Nutrition Pfizer Predoctoral Fellowship (to J Xu). The study sponsors were not involved in study design, data collection, data analysis, data interpretation, report writing or decisions to submit the paper for publication. JX and PAC had final responsibility for the decision to submit for publication.

Clinical Trial Registry Number

The ClinicalTrials.gov identifier of the SELECT trial is NCT00006392 and the identifier of the RAS trial is NCT00063453.

24

References

1. Mocchegiani E, Costarelli L, Giacconi R, Malavolta M, Basso A, Piacenza F, Ostan R, Cevenini E, Gonos ES, Franceschi C, et al. Vitamin E-gene interactions in aging and inflammatory age-related diseases: implications for treatment. A systematic review. Ageing Res Rev. 2014;14:81-101.

2. Brigham KL. Role of free radicals in lung injury. Chest. 1986;89(6):859-63.

3. Dow L, Tracey M, Villar A, Coggon D, Margetts BM, Campbell MJ, Holgate ST. Does dietary intake of vitamins C and E influence lung function in older people? Am J Respir Crit Care Med. 1996;154(5):1401-4.

4. Butland BK, Fehily AM, Elwood PC. Diet, lung function, and lung function decline in a cohort of 2512 middle aged men. Thorax. 2000;55(2):102-8.

5. Schunemann HJ, McCann S, Grant BJ, Trevisan M, Muti P, Freudenheim JL. Lung function in relation to intake of carotenoids and other antioxidant vitamins in a population-based study. Am J Epidemiol. 2002;155(5):463-71.

6. Hanson C, Lyden E, Furtado J, Campos H, Sparrow D, Vokonas P, Litonjua AA. Serum tocopherol levels and vitamin E intake are associated with lung function in the normative aging study. Clin Nutr. 2016;35(1):169-74.

7. Joshi P, Kim WJ, Lee SA. The effect of dietary antioxidant on the COPD risk: the community-based KoGES (Ansan-Anseong) cohort. Int J Chron Obstruct Pulmon Dis. 2015;10:2159-68.

8. Charles LE, Burchfiel CM, Mnatsakanova A, Fekedulegn D, Tinney-Zara C, Joseph PN, Schunemann HJ, Violanti JM, Andrew ME, Ochs-Balcom HM. Antioxidants and pulmonary function among police officers. J Occup Environ Med. 2010;52(11):1124-31.

9. Gilliland FD, Berhane KT, Li YF, Gauderman WJ, McConnell R, Peters J. Children's lung function and antioxidant vitamin, fruit, juice, and vegetable intake. Am J Epidemiol. 2003;158(6):576-84.

10. Tabak C, Smit HA, Rasanen L, Fidanza F, Menotti A, Nissinen A, Feskens EJ, Heederik D, Kromhout D. Dietary factors and pulmonary function: a cross sectional study in middle aged men from three European countries. Thorax. 1999;54(11):1021-6.

11. Hu G, Cassano PA. Antioxidant nutrients and pulmonary function: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Epidemiol. 2000;151(10):975-81.

12. Marchese ME, Kumar R, Colangelo LA, Avila PC, Jacobs DR, Jr., Gross M, Sood A, Liu K, Cook-Mills JM. The vitamin E isoforms alpha-tocopherol and gamma-tocopherol have opposite associations with spirometric parameters: the CARDIA study. Respir Res. 2014;15:31.

13. Schunemann HJ, Grant BJ, Freudenheim JL, Muti P, Browne RW, Drake JA, Klocke RA, Trevisan M. The relation of serum levels of antioxidant vitamins C and E, retinol and carotenoids with pulmonary function in the general population. Am J Respir Crit Care Med. 2001;163(5):1246-55.

14. Grant BJ, Kudalkar DP, Muti P, McCann SE, Trevisan M, Freudenheim JL, Schunemann HJ. Relation between lung function and RBC distribution width in a population-based study. Chest. 2003;124(2):494-500.

15. McKeever TM, Lewis SA, Smit HA, Burney P, Cassano PA, Britton J. A multivariate analysis of serum nutrient levels and lung function. Respir Res. 2008;9:67.

16. Britton JR, Pavord ID, Richards KA, Knox AJ, Wisniewski AF, Lewis SA, Tattersfield AE, Weiss ST. Dietary antioxidant vitamin intake and lung function in the general population. Am J Respir Crit Care Med. 1995;151(5):1383-7.

17. Grievink L, Smit HA, Ocke MC, van 't Veer P, Kromhout D. Dietary intake of antioxidant (pro)-vitamins, respiratory symptoms and pulmonary function: the MORGEN study. Thorax. 1998;53(3):166-71.

18. Chen R, Tunstall-Pedoe H, Bolton-Smith C, Hannah MK, Morrison C. Association of dietary antioxidants and waist circumference with pulmonary function and airway obstruction. Am J Epidemiol. 2001;153(2):157-63.

19. Grievink L, de Waart FG, Schouten EG, Kok FJ. Serum carotenoids, alpha-tocopherol, and lung function among Dutch elderly. Am J Respir Crit Care Med. 2000;161(3 Pt 1):790-5.

20. Grievink L, Smit HA, Veer P, Brunekreef B, Kromhout D. Plasma concentrations of the antioxidants beta-carotene and alpha-tocopherol in relation to lung function. Eur J Clin Nutr. 1999;53(10):813-7.

21. Kelly Y, Sacker A, Marmot M. Nutrition and respiratory health in adults: findings from the health survey for Scotland. The European respiratory journal. 2003;21(4):664-71.

22. Molinie F, Favier A, Kauffmann F, Berr C. Effects of lipid peroxidation and antioxidant status on peak flow in a population aged 59-71 years: the EVA study. Respir Med. 2003;97(8):939-46.

23. Pearson P, Britton J, McKeever T, Lewis SA, Weiss S, Pavord I, Fogarty A. Lung function and blood levels of copper, selenium, vitamin C and vitamin E in the general population. Eur J Clin Nutr. 2005;59(9):1043-8.

24. Guenegou A, Leynaert B, Pin I, Le Moel G, Zureik M, Neukirch F. Serum carotenoids, vitamins A and E, and 8 year lung function decline in a general population. Thorax. 2006;61(4):320-6.

25. Cassano PA, Guertin KA, Kristal AR, Ritchie KE, Bertoia ML, Arnold KB, Crowley JJ, Hartline J, Goodman PJ, Tangen CM, et al. A randomized controlled trial of vitamin E and selenium on rate of decline in lung function. Respir Res. 2015;16:35.

Klein EA, Thompson IM, Jr., Tangen CM, Crowley JJ, Lucia MS, Goodman PJ,
Minasian LM, Ford LG, Parnes HL, Gaziano JM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Jama. 2011;306(14):1549-56.
Alpha-Tocopherol BCCPSG. The effect of vitamin E and beta carotene on the incidence

of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330(15):1029-35.

28. Heart Outcomes Prevention Evaluation Study I, Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):154-60.

29. Gupta SK. Intention-to-treat concept: A review. Perspect Clin Res. 2011;2(3):109-12.

30. Kussmann M, Fay LB. Nutrigenomics and personalized nutrition: science and concept. Per Med. 2008;5(5):447-55.

31. Doring F, Rimbach G, Lodge JK. In silico search for single nucleotide polymorphisms in genes important in vitamin E homeostasis. IUBMB Life. 2004;56(10):615-20.

32. Ferrucci L, Perry JR, Matteini A, Perola M, Tanaka T, Silander K, Rice N, Melzer D, Murray A, Cluett C, et al. Common variation in the beta-carotene 15,15'-monooxygenase 1 gene affects circulating levels of carotenoids: a genome-wide association study. Am J Hum Genet. 2009;84(2):123-33.

33. Major JM, Yu K, Wheeler W, Zhang H, Cornelis MC, Wright ME, Yeager M, Snyder K, Weinstein SJ, Mondul A, et al. Genome-wide association study identifies common variants associated with circulating vitamin E levels. Hum Mol Genet. 2011;20(19):3876-83.

34. Wood AR, Perry JR, Tanaka T, Hernandez DG, Zheng HF, Melzer D, Gibbs JR, Nalls MA, Weedon MN, Spector TD, et al. Imputation of variants from the 1000 Genomes Project modestly improves known associations and can identify low-frequency variant-phenotype associations undetected by HapMap based imputation. PloS one. 2013;8(5):e64343.

35. Major JM, Yu K, Chung CC, Weinstein SJ, Yeager M, Wheeler W, Snyder K, Wright ME, Virtamo J, Chanock S, et al. Genome-wide association study identifies three common variants associated with serologic response to vitamin E supplementation in men. J Nutr. 2012;142(5):866-71.

36. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Jama. 2009;301(1):39-51.

37. Barr RG, Stemple KJ, Mesia-Vela S, Basner RC, Derk SJ, Henneberger PK, Milton DK, Taveras B. Reproducibility and validity of a handheld spirometer. Respir Care. 2008;53(4):433-41.

38. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al. Standardisation of spirometry. The European respiratory journal. 2005;26(2):319-38.

39. Lopez A, Krehl WA, Hodges RE. Relationship between total cholesterol and cholesteryl esters with age in human blood plasma. Am J Clin Nutr. 1967;20(8):808-15.

40. Ford ES, Schleicher RL, Mokdad AH, Ajani UA, Liu S. Distribution of serum concentrations of alpha-tocopherol and gamma-tocopherol in the US population. Am J Clin Nutr. 2006;84(2):375-83.

41. Das S, Forer L, Schonherr S, Sidore C, Locke AE, Kwong A, Vrieze SI, Chew EY, Levy S, McGue M, et al. Next-generation genotype imputation service and methods. Nature genetics. 2016;48(10):1284-7.

42. Fred Hutch Food Frequency Questionnaires (FFQ) [Available from:

https://sharedresources.fredhutch.org/services/food-frequency-questionnaires-ffq.

43. Marchini J, Howie B. Genotype imputation for genome-wide association studies. Nat Rev Genet. 2010;11(7):499-511.

44. Zhan X, Hu Y, Li B, Abecasis GR, Liu DJ. RVTESTS: an efficient and comprehensive tool for rare variant association analysis using sequence data. Bioinformatics. 2016;32(9):1423-6.

45. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26(17):2190-1.

46. Institute of Medicine (US). Panel on Dietary Antioxidants and Related Compounds. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids: A Report of the Panel on Dietary Antioxidants and Related Compounds. Washington, D.C.: National Academy Press; 2000.

47. Traber MG, Winklhofer-Roob BM, Roob JM, Khoschsorur G, Aigner R, Cross C, Ramakrishnan R, Brigelius-Flohe R. Vitamin E kinetics in smokers and nonsmokers. Free Radic Biol Med. 2001;31(11):1368-74.

27

48. Bruno RS, Ramakrishnan R, Montine TJ, Bray TM, Traber MG. {alpha}-Tocopherol disappearance is faster in cigarette smokers and is inversely related to their ascorbic acid status. Am J Clin Nutr. 2005;81(1):95-103.

49. Sontag TJ, Parker RS. Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism. Novel mechanism of regulation of vitamin E status. J Biol Chem. 2002;277(28):25290-6.

50. Parker RS, Sontag TJ, Swanson JE, McCormick CC. Discovery, characterization, and significance of the cytochrome P450 omega-hydroxylase pathway of vitamin E catabolism. Ann N Y Acad Sci. 2004;1031:13-21.

51. van Engen CE, Ofman R, Dijkstra IM, van Goethem TJ, Verheij E, Varin J, Vidaud M, Wanders RJ, Aubourg P, Kemp S, et al. CYP4F2 affects phenotypic outcome in adrenoleukodystrophy by modulating the clearance of very long-chain fatty acids. Biochim Biophys Acta. 2016;1862(10):1861-70.

52. Athinarayanan S, Wei R, Zhang M, Bai S, Traber MG, Yates K, Cummings OW, Molleston J, Liu W, Chalasani N. Genetic polymorphism of cytochrome P450 4F2, vitamin E level and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVENS and TONIC clinical trials. PloS one. 2014;9(4):e95366.

53. Wallstrom P, Wirfalt E, Lahmann PH, Gullberg B, Janzon L, Berglund G. Serum concentrations of beta-carotene and alpha-tocopherol are associated with diet, smoking, and general and central adiposity. Am J Clin Nutr. 2001;73(4):777-85.

54. Vazquez G, Duval S, Jacobs DR, Jr., Silventoinen K. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. Epidemiol Rev. 2007;29:115-28.

55. Ohlson LO, Larsson B, Svardsudd K, Welin L, Eriksson H, Wilhelmsen L, Bjorntorp P, Tibblin G. The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes. 1985;34(10):1055-8.

56. Abdulla KA, Um CY, Gross MD, Bostick RM. Circulating gamma-Tocopherol Concentrations Are Inversely Associated with Antioxidant Exposures and Directly Associated with Systemic Oxidative Stress and Inflammation in Adults. J Nutr. 2018;148(9):1453-61.

57. Waniek S, di Giuseppe R, Esatbeyoglu T, Plachta-Danielzik S, Ratjen I, Jacobs G, Nothlings U, Koch M, Schlesinger S, Rimbach G, et al. Vitamin E (alpha- and gamma-Tocopherol) Levels in the Community: Distribution, Clinical and Biochemical Correlates, and Association with Dietary Patterns. Nutrients. 2017;10(1).

58. Stuetz W, Weber D, Dolle ME, Jansen E, Grubeck-Loebenstein B, Fiegl S, Toussaint O, Bernhardt J, Gonos ES, Franceschi C, et al. Plasma Carotenoids, Tocopherols, and Retinol in the Age-Stratified (35-74 Years) General Population: A Cross-Sectional Study in Six European Countries. Nutrients. 2016;8(10).

59. Talegawkar SA, Johnson EJ, Carithers T, Taylor HA, Jr., Bogle ML, Tucker KL. Total alpha-tocopherol intakes are associated with serum alpha-tocopherol concentrations in African American adults. J Nutr. 2007;137(10):2297-303.

60. Galan P, Viteri FE, Bertrais S, Czernichow S, Faure H, Arnaud J, Ruffieux D, Chenal S, Arnault N, Favier A, et al. Serum concentrations of beta-carotene, vitamins C and E, zinc and selenium are influenced by sex, age, diet, smoking status, alcohol consumption and corpulence in a general French adult population. Eur J Clin Nutr. 2005;59(10):1181-90.

28

61. White E, Kristal AR, Shikany JM, Wilson AC, Chen C, Mares-Perlman JA, Masaki KH, Caan BJ. Correlates of serum alpha- and gamma-tocopherol in the Women's Health Initiative. Ann Epidemiol. 2001;11(2):136-44.

62. Vogel S, Contois JH, Tucker KL, Wilson PW, Schaefer EJ, Lammi-Keefe CJ. Plasma retinol and plasma and lipoprotein tocopherol and carotenoid concentrations in healthy elderly participants of the Framingham Heart Study. Am J Clin Nutr. 1997;66(4):950-8.

63. Ascherio A, Stampfer MJ, Colditz GA, Rimm EB, Litin L, Willett WC. Correlations of vitamin A and E intakes with the plasma concentrations of carotenoids and tocopherols among American men and women. J Nutr. 1992;122(9):1792-801.

64. Knekt P, Seppanen R, Aaran RK. Determinants of serum alpha-tocopherol in Finnish adults. Prev Med. 1988;17(6):725-35.

65. Willett WC, Stampfer MJ, Underwood BA, Speizer FE, Rosner B, Hennekens CH. Validation of a dietary questionnaire with plasma carotenoid and alpha-tocopherol levels. Am J Clin Nutr. 1983;38(4):631-9.

66. Switzer BR, Atwood JR, Stark AH, Hatch JW, Travis R, Ullrich F, Lyden ER, Wu X, Chiu Y, Smith JL. Plasma carotenoid and vitamins a and e concentrations in older African American women after wheat bran supplementation: effects of age, body mass and smoking history. J Am Coll Nutr. 2005;24(3):217-26.

67. Grolier P, Boirie Y, Levadoux E, Brandolini M, Borel P, Azais-Braesco V, Beaufrere B, Ritz P. Age-related changes in plasma lycopene concentrations, but not in vitamin E, are associated with fat mass. Br J Nutr. 2000;84(5):711-6.

	Overall (<i>n</i> = 1144)	Vitamin E + Selenium	Vitamin E + Placebo	$\mathbf{P}_{vitE+Se vs vitE}^2$
		(n = 565)	(n = 579)	
_Age (y) 3	62.6 (6.4)	62.7 (6.3)	62.5 (6.4)	0.57
Ethnicity, N (%) ³				0.64
European American	874 (76)	435 (77)	439 (76)	
African American	270 (24)	130 (23)	140 (24)	
Smoking Status, N (%) ⁴				0.98
Never	364 (32)	181 (32)	183 (32)	
Former	564 (49)	277 (49)	287 (50)	
Current	216 (19)	107 (19)	109 (19)	
BMI (kg/m ²) ³	28.9 (4.6)	28.4 (4.6)	29.3 (4.6)	0.0019
Height (cm) ³	176.6 (7.1)	176.6 (7.0)	176.7 (7.1)	0.83
FEV ₁ (mL) ³	2986.8 (680.8)	2990.4 (669.1)	2983.2 (692.5)	0.86

Table 1. Characteristics of male participants with vitamin E supplementation in the Respiratory Ancillary Study (n = 1,144)¹

¹Data are presented as mean (standard deviation [SD]) in the table, and measured at baseline, unless otherwise noted.

² The p-value is to compare whether each characteristic in the vitE+Se arm significantly differed from that in the vitE arm. P-value is based on the t test for continuous variables or based on the chi-square test for categorical variables in the vitamin E arms (vitE+Se arm versus vitE arm). Significant P < 0.05 is in bold.

³ Measured at baseline.

⁴ Smoking status refers to the status throughout the study such that former smoker is defined as someone who had quitted smoking before getting enrolled in the study, whereas current smoker is defined as intermittent or persistent smokers over the course of the study.

Abbreviations: BMI, body mass index; FEV_1 , forced expiratory volume in the 1st second, vitE, vitamin E supplementation only arm; vitE+Se, vitamin E + selenium supplementation arm.

	ΔRaw α-TOH			ΔAdjusted α-TOH ²		
	β (SE) ³	95% CI	P value ⁴	β (SE) ³	95% CI	P value ⁴
Main effect model $(n = 1, 142)^5$	·			2		
Full sample	0.23 (0.20)	(-0.17, 0.63)	0.26	0.96 (0.60)	(-0.23, 2.14)	0.11
Adherent sample $^{6}(n = 775)$	0.24 (0.25)	(-0.26, 0.73)	0.35	1.36 (0.78)	(-0.17, 2.89)	0.082
Adherent sample who responded to	0.67 (0.31)	(0.054, 1.28)	0.033	2.22 (0.90)	(0.45, 3.99)	0.014
the vitE supplement 6,7 ($n = 680$)						
Smoking interaction model $(n = 1, 142)^5$		Pinteraction=0.013 ⁸			Pinteraction=0.032 ⁸	
Never smokers $(n = 364)$	0.83 (0.35)	(0.15, 1.51)	0.017	2.43 (1.01)	(0.44, 4.42)	0.017
Former smokers $(n = 564)$	-0.41 (0.30)	(-0.99, 0.17)	0.17	-0.64 (0.86)	(-2.32, 1.04)	0.45
Current smokers $(n = 214)$	0.73 (0.48)	(-0.20, 1.67)	0.12	2.75 (1.57)	(-0.32, 5.82)	0.079

Table 2. Association of plasma change in α-tocopherol after 3-year vitamin E supplementation, and its interaction with

smoking status, on annual rate of change in FEV1¹

¹All models were adjusted for age at baseline, height, ancestry, smoking status, smoking dose at baseline, treatment arm, baseline α -

tocopherol, baseline γ -tocopherol, and baseline free cholesterol (only in the model with raw α -tocopherol values).

² Δ Adjusted α -TOH refers to the change in free-cholesterol-adjusted α -tocopherol concentration from baseline to year 3.

 $^{3}\beta$ was the coefficient of the $\Delta\alpha$ -TOH \times time term in the main effect model. For the smoking interaction model, it was the coefficient

of the $\Delta \alpha$ -TOH × time term for the reference group when each smoking status was set as the reference.

⁴ P-value of the $\Delta \alpha$ -TOH × time term to test the association of $\Delta \alpha$ -TOH on rate of change in FEV₁. For the smoking interaction model,

it was the p-value of $\Delta \alpha$ -TOH × time term for each smoking group (when it was set as the reference) in the model that included all

smoking status. Significant P < 0.05 is in bold and P < 0.10 is italicized.

⁵ 2 current smokers had missing data for smoking dose and thus were excluded in the statistical model.

⁶ Adherent participants (defined as taking at least 80% of the supplement pills) during the 3 years of supplementation.

⁷Responder was defined as $\Delta raw \alpha$ -TOH greater than the mean change in the placebo arm (-3.8 μ mol/L) after 3-year supplementation.

⁸ The P_{interaction} value was for the 3-way interaction term ($\Delta \alpha$ -TOH × time × smoking status) to test whether the association of $\Delta \alpha$ -TOH on rate of change in FEV₁ differed by smoking status.

Abbreviations: CI, confidence interval.

Table 3. Factors associated with plasma change in α-tocopherol after 3-year vitamin E supplementation in the Respiratory

Ancillary Study $(n = 1,135)^{1}$

	$\Delta \mathbf{Raw} \alpha$ -TOH ²		Δ Adjusted α -TOH ³	
	β (SE) ⁴	P-value ⁵	β (SE) ⁴	P-value ⁵
Baseline α-tocopherol ⁶	-0.64 (0.052)	<0.0001	-0.38 (0.039)	<0.0001
Baseline γ-tocopherol ⁶	0.82 (0.17)	<0.0001	1.31 (0.14)	<0.0001
Cholesterol (µmol/L)	0.0024 (0.00058)	<0.0001		
Ancestry				
White	4.43 (0.93)	<0.0001	1.71 (0.30)	<0.0001
African American	Ref	ref	ref	ref
Treatment arm				
Vitamin E + Selenium	-0.30 (0.73)	0.68	0.30 (0.24)	0.21
Vitamin E + Placebo	Ref	ref	ref	ref
Age (year)	-0.078 (0.059)	0.19	0.0082 (0.019)	0.67
BMI (kg/m ²)	0.044 (0.080)	0.58	0.013 (0.026)	0.63
Smoking Status		Type III $= 0.53$		Type III=0.40
Current Smokers	-1.16 (1.09)	0.29	-0.46 (0.35)	0.21
Former Smokers	-0.11 (0.83)	0.89	-0.039 (0.27)	0.88
Never Smokers	Ref	ref	ref	ref
Baseline selenium concentration	-0.0024(0.0056)	0.67	-0.00064 (0.0018)	0.72
(parts per billion)				
Total vitamin C intake (mg)	-0.00041 (0.0014)	0.78	0.00025 (0.00046)	0.60
Dietary fiber intake (gram)	0.043 (0.035)	0.22	0.0052 (0.011)	0.65
Alcohol intake (gram)	-0.0016 (0.018)	0.93	-0.0049 (0.0060)	0.41

¹ All factors shown in the table were modeled in the same multiple linear regression. Participants in the vitamin E + selenium arm and in the vitamin E + placebo arm were included. 9 participants had missing vitamin C, fiber, and alcohol intake and thus the sample size for this analysis was 1135.

² Total variability explained, $R^2=18.7\%$.

 $^{3}\Delta$ Adjusted α -TOH refers to the change in free-cholesterol-adjusted α -tocopherol concentration from baseline to year 3. Total variability explained, R²=19.5%.

⁴ β was the coefficient of the association of each factor with the change in α -tocopherol phenotype.

⁵ For each categorical variable, the type III p-value indicates whether the categorical variable was significant when being included in the model, while the p-value of each categorical level (except the reference group) indicates whether the coefficient significantly differed from that of the reference group. For each continuous variable, the p-value indicates whether the coefficient significantly differed from zero.

⁶ The unit for baseline α -tocopherol and γ -tocopherol concentrations is μ mol/L when the outcome is the raw plasma change in α -tocopherol concentration, and the unit is μ mol/mmol free cholesterol when the outcome is the plasma change in free-cholesterol-adjusted α -tocopherol concentration.

Abbreviations: BMI, body mass index.

	$\Delta \mathbf{Raw}$	ΔRaw α-TOH		l α-TOH ¹
	β (SE) ²	P-value ³	β (SE) ²	P-value ³
Unadjusted model				
Overall $(n = 555)$	2.46 (0.83)	0.0034	0.48 (0.28)	0.080
- EA ($n = 417$)	2.27 (0.93)	0.015	0.34 (0.30)	0.25
- AA $(n = 138)$	1.02 (2.25)	0.65	0.30 (0.80)	0.70
Adjusted model ⁴				
Overall $(n = 548)^{5}$	2.36 (0.80)	0.0032	0.25 (0.26)	0.33
- EA ($n = 413$)	2.42 (0.87)	0.0058	0.23 (0.28)	0.40
- AA (<i>n</i> = 135)	1.42 (2.05)	0.49	0.43 (0.74)	0.56

Table 4. The association of rs2108622-T with plasma change in α-tocopherol for male participants randomized to the vitamin

E only arm (400 IU/day *all rac-a*-tocopherol) in the Respiratory Ancillary Study (n = 555)

¹ Δ Adjusted α -TOH refers to the change in free-cholesterol-adjusted α -tocopherol concentration from baseline to year 3.

 $^{2}\beta$, the coefficient of the association of the rs2108622-T allele with the change in α -tocopherol phenotype.

³ P-value of the association coefficient. Significant P < 0.025 (Bonferroni correction for testing 2 SNPs) is in bold.

⁴ Adjusted for age at baseline, BMI at baseline, ancestry, smoking status, plasma selenium concentration, total vitamin C intake,

dietary fiber intake, alcohol intake, baseline α -tocopherol, baseline γ -tocopherol, and baseline free cholesterol (only in the model with

raw α-tocopherol). 7 participants had missing vitamin C, fiber, and alcohol intake and thus the sample size for the adjusted model was

548.

⁵ Total variability explained, R^2 =18.3% for raw change in α -TOH (19.2% for change in free-cholesterol-adjusted α -TOH), and baseline concentrations of α -TOH, γ -TOH, free cholesterol, ancestry, and rs2108622-T explained 9.2%, 1.7%, 1.3%, 1.7%, and 1.3% of the variability, respectively.

Abbreviations: AA, African ancestry; EA, European ancestry.

37

Legends for figures

Figure 1. Flowchart of sample size included in this study

Figure 2. Frequency distribution of the change in plasma α -tocopherol (μ mol/L) from baseline to year 3 in RAS. The black vertical line denotes the mean change in plasma α -tocopherol (-3.8 μ mol/L) in the placebo arm. Vitamin E (vitE) groups include participants in the vitE supplementation only arm and vitE + Selenium supplementation arm. Responders in the vitE groups are defined as having a change in plasma α -tocopherol greater than -3.8 μ mol/L. The mean and SD of change in plasma α -tocopherol is shown in each subfigure as well as the proportions of participants who had a change greater than -3.8 μ mol/L.



